Satish waman Wagh has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
SUPRIYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Satish Waman Wagh, the promoter of Supriya Lifescience, along with 16 members of the promoter group (including family members and group entities like Supriya Medi-Chem and Lote Industries Testing Laboratory Association), have filed a mandatory annual disclosure under SEBI's Takeover Regulations. They confirm that no encumbrance — meaning no pledging, lien, or charge — was created on their shares, directly or indirectly, during the financial year ended March 31, 2025. This is a routine year-end compliance filing required of all promoters, and not a new transaction.
This is a neutral, routine filing with no immediate effect on the stock. It reassures shareholders that the promoter group has not pledged any of their holdings, which means no risk of forced selling due to margin calls. No buy or sell action is warranted based on this disclosure alone.